Danaher (NYSE:DHR) Stock Price Target Raised at Stifel Nicolaus

Key Points

• Stifel Nicolaus raised Danaher’s price target from $220 to $260 and maintained a “buy” rating, implying 11.11% upside from the previous close.
• Danaher reported quarterly EPS of $2.11, beating the $1.92 consensus estimate, while revenue rose 8.3% year over year to $6.55 billion, roughly in line with expectations.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $237.68; the company also raised its full-year adjusted EPS outlook to $8.57–$8.62.

Danaher (NYSE:DHR - Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from $220.00 to $260.00 in a report released on Thursday, Benzinga reports. The firm presently has a "buy" rating on the conglomerate's stock. Stifel Nicolaus' price target suggests a potential upside of 11.11% from the company's previous close.

Several other equities research analysts have also issued reports on DHR. Guggenheim increased their target price on shares of Danaher from $200.00 to $250.00 and gave the stock a "buy" rating in a research note on Thursday, October 1st. Wall Street Zen lowered Danaher from a "buy" rating to a "hold" rating in a research note on Sunday. TD Cowen lifted their price target on Danaher from $236.00 to $255.00 and gave the company a "buy" rating in a research note on Tuesday, October 13th. Morgan Stanley upped their price target on Danaher from $220.00 to $240.00 and gave the stock an "overweight" rating in a report on Monday, October 12th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $240.00 price target on shares of Danaher in a research report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $237.68.

Danaher Price Performance

NYSE:DHR opened at $233.99 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The firm has a market cap of $164.49 billion, a price-to-earnings ratio of 41.56, a price-to-earnings-growth ratio of 2.82 and a beta of 0.76. The company has a 50 day moving average price of $215.25 and a 200-day moving average price of $196.84. Danaher has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.19. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.55 billion during the quarter, compared to analysts' expectations of $6.56 billion. During the same period in the previous year, the business posted $1.89 EPS. The business's revenue was up 8.3% compared to the same quarter last year. Equities research analysts forecast that Danaher will post 8.53 EPS for the current year.

Institutional Trading of Danaher

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Danaher in the 2nd quarter valued at about $10,492,520,000. Wellington Management Group LLP increased its stake in Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate's stock worth $3,108,031,000 after buying an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC acquired a new position in shares of Danaher during the second quarter valued at approximately $1,456,317,000. Generation Investment Management LLP acquired a new position in shares of Danaher during the second quarter valued at approximately $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in shares of Danaher during the second quarter valued at approximately $993,846,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported adjusted earnings of $2.11 per share, above the $1.92 analyst consensus and up from $1.89 a year earlier. Revenue rose 8.3% to $6.55 billion, narrowly below or effectively in line with the $6.56 billion estimate. Danaher Reports Third Quarter 2026 Results
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, signaling confidence that improving customer demand and operating performance will continue. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: Biotechnology was a key growth driver: orders increased at a mid-teens rate, while stronger profitability in the segment helped produce the earnings beat. Management also cited improving trends across several end markets. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Management highlighted artificial-intelligence capabilities as a potential long-term growth opportunity in drug discovery, describing Danaher as having the foundational technologies—or “building blocks”—to participate in the market. Danaher says it has building blocks for AI drug discovery growth
• Neutral Sentiment: The acquisition of Masimo helped offset weaker respiratory diagnostic sales, suggesting integration benefits but also continued softness in parts of the diagnostics portfolio. Danaher’s Masimo acquisition offsets drops in respiratory diagnostic sales
• Negative Sentiment: Revenue did not materially exceed expectations, and the ongoing CEO transition could create uncertainty around execution and Danaher’s strategic priorities despite the stronger outlook. Danaher drops after Q3 revenue miss amid CEO transition

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.